Use of H-2 antagonists for treatment of gingivitis

• US 5,294,433 A
• Filed: 03/05/1993
• Issued: 03/15/1994
• Est. Priority Date: 04/15/1992
• Status: Expired due to Term

• Current Assignee: Boston University
• Original Assignee: The Procter & Gamble Company
• Inventors: Ebel, James P., Singer, Robert E.
• Primary Examiner(s): ROSE, SHEP K
• Application Number:
  US08/019,782
• Time in Patent Office: 375 Days
• Field of Search: 514/399, 514/406, 514/900, 514/902, 424/52, 424/54
• US Class Current: 424/52
• CPC Class Codes: A61K 31/34 having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• CPC Class Codes: A61K 31/41 having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/425 Thiazoles
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The subject invention relates to methods for prevention or treatment of gingivitis or periodontitis comprising topical administration, to gingival tissues of the oral cavity, of a composition comprising a safe and effective amount of a selective histamine-2 receptor antagonist compound, and oral care compositions used therefore.

Claims

1. A method for prevention or treatment of gingivitis or soft tissue aspects of periodontitis comprising topical administration, to gingival tissues of the oral cavity, of a fluoride toothpaste of a composition comprising a safe and effective amount of a selective H-2 antagonist.

2. The method of claim 1 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-52368, SKF-94482, BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728, and HB-408.

3. The method of claim 1 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine, roxatidine, nizatidine and mifentidine.

4. The method of claim 1 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine, and nizatidine.

5. The method of claim 1 wherein the selective H-2 antagonist is cimetidine.

6. The method of claim 1 wherein the selective H-2 antagonist is ranitidine.

7. The method of any of claims 1, 4, 5 and 6 wherein the composition comprises from about 0.01% to about 10% of the selective H-2 antagonist.

8. A fluoride toothpaste or toothpaste or tooth gel composition comprising:

(a) a safe and effective amount of a selective H-2 antagonist; and

(b) a toothpaste or tooth gel carrier comprising a dental abrasive, a surfactant, a humectant, a flavoring or sweetening agent, and

(c) a safe and effective amount of a fluoride anticaries agent water.

9. The composition of claim 8 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-52368, SKF-94482, BL-6341A, ICI-162846, ramixotidine, Wy-5727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728, and HB-408.

10. The compositions of claim 9 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine, roxatidine, nizatidine and mifentidine.

11. The composition of claim 9 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine and nizatidine.

12. The composition of claim 9 wherein the selective H-2 antagonist is cimetidine.

13. The composition of claim 9 wherein the selective H-2 antagonist is ranitidine.